<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="567">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>16/09/2005</approvaldate>
  <actrnumber>ACTRN12605000419662</actrnumber>
  <trial_identification>
    <studytitle>IBCSG 26-02 / BIG 4-02: Premenopausal Endocrine Responsive Chemotherapy Trial</studytitle>
    <scientifictitle>IBCSG 26-02 / BIG 4-02: Premenopausal Endocrine Responsive Chemotherapy Trial  A phase III trial evaluating the role of chemotherapy as adjuvant therapy for premenopausal women with endocrine responsive breast cancer who receive endocrine therapy.</scientifictitle>
    <utrn />
    <trialacronym>PERCHE  Premenopausal Endocrin</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR585</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>IBCSG 26-02 / BIG 4-02 (PERCHE) is being conducted internationally by the International Breast Cancer Study Group (IBCSG).  The study is coordinated in Australia and New Zealand by the Australian and New Zealand Breast Cancer Trials Group (ANZ BCTG).

This trial will evaluate the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or exemestane for 5 years.  The use of chemotherapy will be determined by randomization.  The method of ovarian function suppression (GnRH analogue for 5 years, surgical oophorectomy or ovarian irradiation) and the choice of tamoxifen or exemestane will be determined by the investigator.

IBCSG 26-02 / BIG 4-02 (PERCHE) is an international, multicentre, randomised phase III clinical trial of 1750 premenopausal  women who have had histologically or cytologically confirmed, receptor-positive primary breast cancer for whom there is an uncertain role for adding chemotherapy to the adjuvant treatment program.
 
Women will be randomised in a 2-arm design to receive one of the following:

a. Chemotherapy + Ovarian Function Suppression (triptorelin) + Tamoxifen/Exemestane
b. Ovarian Function Suppression (triptorelin) + Tamoxifen/Exemestane
All hormonal treatment will be for 5 years.</interventions>
    <comparator>a. Chemotherapy + Ovarian Function Suppression (triptorelin) + Tamoxifen/Exemestane
b. Ovarian Function Suppression (triptorelin) + Tamoxifen/Exemestane
All hormonal treatment will be for 5 years. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare disease free survival between treatment arms.</outcome>
      <timepoint>At first confirmation of relapse (local, regional or distant), contralateral breast cancer, second (non-breast) primary tumour and/death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare overall survival</outcome>
      <timepoint>At time of death from any cause</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Systemic disease-free survival</outcome>
      <timepoint>At the time of systemic relapse, appearance of second (non-breast) primary tumour, or death, whichever occurs first.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sites of first treatment failure</outcome>
      <timepoint>At the time of first treatment failure.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Late side effects of early menopause</outcome>
      <timepoint>At the time of menopause.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of second (non-breast) malignancies </outcome>
      <timepoint>At the time of incidence of second (non-breast) malignancies</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Causes of death without cancer event between the treatment arms.</outcome>
      <timepoint>At the time of death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pre-menopausal women with histologically proven, completely resected, hormone receptor positive breast cancer confined to the breast and axillary nodes without metastases; axillary node dissection or a negative axillary sentinel node biopsy is required; geographically accessible for follow up; written informed consent provided.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Post-menopausal women; distant metastatic disease; locally advanced inoperable breast cancer; supraclavicular node involvement; enlarged internal mammary nodes; bilateral invasive breast cancer; positive final margins; clinically detectable residual axillary disease; history of prior ipsilateral or contralateral invasive breast cancer; previous or concomitant malignancy; other non-malignant systemic diseases that would prevent prolonged follow-up; bilateral oophorectomy or ovarian irradiation; pregnant or lactating at randomisation, desire a pregnancy within 5 years or plan to use additional hormone therapy during next 5 years (including hormonal contraception); neoadjuvant or adjuvant endocrine therapy after breast cancer diagnosis; tamoxifen or other SERM or HRT within 1 year prior to breast cancer diagnosis; prior neoadjuvant or adjuvant chemotherapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The ANZ BCTG Statistical Centre at the NHMRC Clinical Trials Centre, University of Sydney will provide a central randomisation service by fax for all Australian and New Zealand institutions. At the time of study entry all participants will be allocated a treatment code via a web-based randomization system and study drug will be supplied in accordance with the treatment code.</concealment>
    <sequence>Computer generated stratified blocks.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>22/11/2004</anticipatedstartdate>
    <actualstartdate>1/05/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/10/2006</actualenddate>
    <samplesize>1750</samplesize>
    <actualsamplesize>29</actualsamplesize>
    <recruitmentstatus>Stopped early</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>18/09/2015</actuallastvisitdate>
    <dataanalysis>Data collected is being analysed</dataanalysis>
    <withdrawnreason>Participant recruitment difficulties</withdrawnreason>
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australia and New Zealand Breast Cancer Trials Group Ltd</primarysponsorname>
    <primarysponsoraddress>PO BOX 155
HRMC NSW 2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>ANZ Breast Cancer Trials Group</fundingname>
      <fundingaddress>PO BOX 155
HRMC NSW 2310</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>International Breast Cancer Study Group</sponsorname>
      <sponsoraddress>Effingerstrasse 40
3008 Bern</sponsoraddress>
      <sponsorcountry>Switzerland</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Estrogen can stimulate the growth of breast tumor cells. Suppression of ovarian function combined with hormone therapy may fight breast cancer by reducing the production of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether suppression of ovarian function and hormone therapy are more effective with or without chemotherapy in treating breast cancer.
This randomized phase III trial is studying how well giving ovarian-function suppression together with hormone therapy and chemotherapy works compared to ovarian-function suppression and hormone therapy alone in treating premenopausal women with resected breast cancer.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Riverina Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>John F Forbes</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 49850113</phone>
      <fax>+61 2 49601539</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Corinna Beckmore</name>
      <address>ANZBCTG
PO BOX 155
HRMC NSW 2310</address>
      <phone>+61 2 4985 0159</phone>
      <fax>+61 2 49850141</fax>
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Prue Francis</name>
      <address>Medical Oncology Department 
Peter MacCallum Cancer Centre
Locked Bag 1
A'Beckett Street
MELBOURNE      VIC   8006</address>
      <phone>+61 (03) 9656-1111</phone>
      <fax />
      <email>enquiries@anzbctg.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>